首页> 外文期刊>Journal of immunology research. >LINC01355 Contributes to Malignant Phenotype of Oral Squamous Cell Carcinoma and Cytotoxic T Cell Infiltration via Activating Notch Signaling Pathway
【24h】

LINC01355 Contributes to Malignant Phenotype of Oral Squamous Cell Carcinoma and Cytotoxic T Cell Infiltration via Activating Notch Signaling Pathway

机译:LINC01355通过激活Notch信号通路有助于口腔鳞状细胞癌和细胞毒性T细胞渗透的恶性表型

获取原文
           

摘要

LINC01355 has been demonstrated to be dysregulated in several cancers. However, the exact molecular function of LINC01355 in the pathogenesis of OSCC remains unstudied. Here, we reported the effect of LINC01355 in OSCC and investigated the mechanisms. Firstly, we found that the results indicated LINC01355 was increased in OSCC cells. Knockdown of LINC01355 repressed OSCC cell proliferation, migration, and invasion. Recently, immunotherapy is a significant method for the treatment of cancers, in which CD8+ T cells exhibit a significant role. The influence of LINC01355 on the antitumor activity of CD8+ T cells was also focused in this study. As shown, the silence of LINC01355 could repress OSCC tumor growth via inducing CD8+ T cell immune responses. In addition, we found that downregulation of LINC01355 significantly restrained CD8+ T cell apoptosis, induced CD8+ T cell percentage, and enhanced the cytolysis activity when cocultured with OSCC cells. It has been reported that the Notch pathway represses CD8+ T cell activity in cancer patients. In our present study, we displayed that lack of LINC01355 suppressed OSCC malignant behaviors and enhanced the antitumor activity of CD8+ T cells via inactivating Notch signaling. We showed that decreased LINC01355 significantly restrained the Notch signal via a decrease of Notch-1, JAG-1, and HES-1. Repression of Notch1 reversed the effect of LINC01355 in OSCC cells. In conclusion, it was implied that LINC01355 might induce the development of OSCC via modulating the Notch signal pathway, which could provide a candidate therapeutic target for OSCC.
机译:LINC01355已被证明在几种癌症中具有吸诵。然而,LINC01355在OSCC发病机制中的确切分子函数仍未有。在这里,我们报告了LINC01355在OSCC中的影响并调查了机制。首先,我们发现结果表明LINC01355在OSCC细胞中增加。 LINC01355敲低压抑OSCC细胞增殖,迁移和入侵。最近,免疫疗法是治疗癌症的重要方法,其中CD8 + T细胞表现出具有重要作用。 LINC01355对CD8 + T细胞抗肿瘤活性的影响还集中于本研究。如图所示,LINC01355的沉默可以通过诱导CD8 + T细胞免疫应答来压制OSCC肿瘤生长。此外,我们发现LINC01355的下调显着抑制了CD8 + T细胞凋亡,诱导了CD8 + T细胞百分比,并在通过OSCC细胞与OSCC细胞共同化时增强了细胞分解活性。据报道,陷波途径在癌症患者中抑制CD8 + T细胞活性。在我们目前的研究中,我们展示缺乏LINC01355抑制了OSCC恶性行为,并通过灭活凹口信号传导来增强CD8 + T细胞的抗肿瘤活性。我们表明,下降的LINC01355通过Notch-1,Jag -1和HES-1的减少显着地限制了凹口信号。 Notch1的抑制逆转了LINC01355在OSCC细胞中的影响。总之,暗示LINC01355可以通过调节凹口信号途径来诱导OSCC的开发,这可以为OSCC提供候选治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号